Singapore develops potential antibody treatment for yellow fever – BSA bureau

TY014 is developed by Rapid Response Strategy and can be extended to treat other infectious disease indications
Researchers from Antimicrobial Resistance (AMR), an interdisciplinary group at Singapore-MIT Alliance for Research and Technology (SMART), MIT’s research enterprise in Singapore, have developed TY014, a potential antibody treatment for yellow fever. SMART AMR collaborated with researchers from Massachusetts Institute of Technology (MIT), and local institutions such as the Singapore Ge…

Click here to view the original article.